50242-554-86 : NDC 2026 Code

50242-554-86 : Ocrelizumab And Hyaluronidase ( Ocrevus Zunovo )

Additionally :

You can get information about “50242-554-86” NDC code in 50242-554-86 in HTML format

HTML | 50242-554-86 in TXT (Plain Text) format

TXT | 50242-554-86 in PDF (Portable Document Format)

PDF | 50242-554-86 in XML format

XML formats.

NDC Code : 50242-554-86 – JSON Data Format

                
{
  "NDC": {
    "NDCCode": "50242-554-86",
    "PackageDescription": "1 VIAL, SINGLE-USE in 1 CARTON (50242-554-86)  / 23 mL in 1 VIAL, SINGLE-USE",
    "NDC11Code": "50242-0554-86",
    "ProductNDC": "50242-554",
    "ProductTypeName": "HUMAN PRESCRIPTION DRUG",
    "ProprietaryName": "Ocrevus Zunovo",
    "ProprietaryNameSuffix": null,
    "NonProprietaryName": "Ocrelizumab And Hyaluronidase",
    "DosageFormName": "INJECTION, SOLUTION",
    "RouteName": "SUBCUTANEOUS",
    "StartMarketingDate": "20240913",
    "EndMarketingDate": null,
    "MarketingCategoryName": "BLA",
    "ApplicationNumber": "BLA761371",
    "LabelerName": "Genentech, Inc.",
    "SubstanceName": "HYALURONIDASE (HUMAN RECOMBINANT); OCRELIZUMAB",
    "StrengthNumber": "23000; 920",
    "StrengthUnit": "U/23mL; mg/23mL",
    "Pharm_Classes": "Antibodies, Monoclonal [CS], Antibodies, Monoclonal, Humanized [CS], CD20-directed Antibody Interactions [MoA], CD20-directed Cytolytic Antibody [EPC], Endoglycosidase [EPC], Glycoside Hydrolases [CS]",
    "DEASchedule": null,
    "Status": "Active",
    "LastUpdate": "2025-12-18",
    "PackageNdcExcludeFlag": "N",
    "ProductNdcExcludeFlag": "N",
    "ListingRecordCertifiedThrough": "20261231",
    "StartMarketingDatePackage": "20240913",
    "EndMarketingDatePackage": null,
    "SamplePackage": "Y"
  }
}